[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Fabry, Pompe, and Gaucher disease are each caused by a different missing lysosomal enzyme, but treated with the same underlying approach: correct a patient's own hematopoietic stem cells ex vivo, then re-infuse them. FDA's INTERACT feedback confirmed CMC knowledge -- vector backbone, packaging system, process steps -- can carry across programs where those elements are conserved.
That's the basis for describing Live-cel as a platform rather than three unrelated single-asset programs -- manufacturing and regulatory learning compounds across the three.
This is platform logic, not clinical proof across all three diseases; Fabry (GT-GLA-S03) remains the only program with a defined regulatory pathway and trial-stage data so far.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Brian Christie @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0